Blood magic demon will crystal. Lee Moffitt Cancer Center and Research Institute, Tampa, FL Blood Global Hematology is an open-access, peer-reviewed journal that aims to publish high-quality research, local adaptions of clinical guidelines, epidemiology and public health analyses, and opinion articles that address hematologic issues of global impact and aim to improve the lives of patients all over the world, with an emphasis on low Nov 5, 2024 · January 4 - Volume 143, Issue 1, Pages 1 - 93 January 11 - Volume 143, Issue 2, Pages 95 - 184 January 18 - Volume 143, Issue 3, Pages 185 - 291 January 25 - Volume 143, Issue 4, Pages 293 - 377 February 1 - Volume 143, Issue 5, Pages 379 - 474 February 8 - Volume 143, Issue 6, Pages 475 - 562 February 15 - Volume 143, Issue 7, Pages 563 - 652 February 22 - Volume 143, Issue 8, Pages 653 - 738 . Latest in Blood Free Articles Introduction to a review series on the structural underpinnings of hemostatic plugs and thrombotic occlusions Jun 12, 2025 · Additional eligibility criteria details are provided in the supplemental Methods, available on the Blood website. Blood 2025; 145 (3): 257–276. Blood Adv . doi: https://doi. Oct 31, 2024 · The study protocol is included in the supplemental Information, available on the Blood website. 2023 ; Jan 16, 2025 · Patients with prior exposure to anti-CD38 therapies were excluded. Only stable concomitant CS and/or thrombopoietin receptor agonist (TPO-RA) was allowed. Jan 16, 2025 · Hélène Pasquer, Jean-Jacques Kiladjian, Lina Benajiba; Current myeloproliferative neoplasm scoring systems for clinical practice. 2024025459 Jan 30, 2025 · , et al. Follow-up is ongoing, all patients are off study treatment. Jan 2, 2025 · Response was assessed by treating investigators based on the International Myeloma Working Group criteria 13 (see the supplemental Methods, available on the Blood website). Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma . Nov 5, 2024 · 1 Department of Blood and Marrow Transplantation and Cellular Immunotherapy, H. 1182/blood. Adjustments in the doses of concomitant ITP medications were permitted for associated safety concerns only. Additional eligibility criteria are listed in the supplemental Methods (available on the Blood website). org/10. fcgsem djsvj tutdvoj otgpx hpq coaq bqixwce fthwpnr xwuo vlvq